Vontobel Holding Ltd. Sells 7,982 Shares of Alkermes plc (NASDAQ:ALKS)

Vontobel Holding Ltd. lowered its position in shares of Alkermes plc (NASDAQ:ALKS) by 14.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 48,279 shares of the company’s stock after selling 7,982 shares during the quarter. Vontobel Holding Ltd.’s holdings in Alkermes were worth $1,389,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. V Square Quantitative Management LLC bought a new stake in shares of Alkermes during the third quarter worth $29,000. Blue Trust Inc. grew its stake in shares of Alkermes by 2,394.5% during the fourth quarter. Blue Trust Inc. now owns 1,821 shares of the company’s stock worth $51,000 after purchasing an additional 1,748 shares during the period. Archer Investment Corp grew its stake in shares of Alkermes by 28.6% during the third quarter. Archer Investment Corp now owns 4,500 shares of the company’s stock worth $126,000 after purchasing an additional 1,000 shares during the period. KBC Group NV grew its stake in shares of Alkermes by 18.8% during the third quarter. KBC Group NV now owns 4,890 shares of the company’s stock worth $137,000 after purchasing an additional 774 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Alkermes by 17.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,956 shares of the company’s stock worth $164,000 after purchasing an additional 904 shares during the period. Institutional investors own 95.21% of the company’s stock.

Insider Activity at Alkermes

In other news, SVP Christian Todd Nichols sold 5,208 shares of the firm’s stock in a transaction that occurred on Wednesday, November 27th. The stock was sold at an average price of $29.15, for a total value of $151,813.20. Following the completion of the sale, the senior vice president now directly owns 60,703 shares of the company’s stock, valued at $1,769,492.45. This trade represents a 7.90 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, EVP Craig C. Hopkinson sold 9,221 shares of the firm’s stock in a transaction that occurred on Thursday, December 5th. The shares were sold at an average price of $31.50, for a total value of $290,461.50. Following the completion of the sale, the executive vice president now directly owns 59,730 shares of the company’s stock, valued at approximately $1,881,495. The trade was a 13.37 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 323,608 shares of company stock valued at $10,854,725. Insiders own 4.89% of the company’s stock.

Analysts Set New Price Targets

ALKS has been the subject of a number of analyst reports. JPMorgan Chase & Co. decreased their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating for the company in a research note on Friday, October 25th. Deutsche Bank Aktiengesellschaft began coverage on Alkermes in a research note on Tuesday, February 11th. They set a “buy” rating and a $40.00 price objective for the company. Piper Sandler reissued an “overweight” rating and issued a $37.00 target price (down from $38.00) on shares of Alkermes in a research note on Friday, October 25th. The Goldman Sachs Group boosted their target price on Alkermes from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday. Finally, StockNews.com raised Alkermes from a “buy” rating to a “strong-buy” rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating, nine have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.25.

Alkermes Stock Performance

Shares of NASDAQ ALKS opened at $35.89 on Tuesday. The stock has a 50 day moving average price of $30.40 and a 200 day moving average price of $28.81. Alkermes plc has a 52 week low of $22.90 and a 52 week high of $36.25. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.03 and a current ratio of 3.45. The stock has a market capitalization of $5.81 billion, a PE ratio of 18.41, a price-to-earnings-growth ratio of 1.83 and a beta of 0.49.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.81 by $0.11. Alkermes had a return on equity of 24.92% and a net margin of 22.15%. Analysts predict that Alkermes plc will post 2.23 earnings per share for the current fiscal year.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.